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Abstract
Background: Nontypable Haemophilus influenzae (NTHi) is a common bacterial pathogen causing
human respiratory tract infections under permissive conditions such as chronic obstructive
pulmonary disease. Inhalation of β2-receptor agonists is a widely used treatment in patients with
chronic obstructive pulmonary disease. The aim of this study was to determine the effect of
inhalation of β2 agonists on the host immune response to respiratory tract infection with NTHi.
Methods: Mouse alveolar macrophages were stimulated in vitro with NTHi in the presence or
absence of the β2 receptor agonists salmeterol or salbutamol. In addition, mice received salmeterol
or salbutamol by inhalation and were intranasally infected with NTHi. End points were pulmonary
inflammation and bacterial loads.
Results: Both salmeterol and salbutamol inhibited NTHi induced tumor necrosis factor-α (TNFα)
release by mouse alveolar macrophages in vitro by a β receptor dependent mechanism. In line,
inhalation of either salmeterol or salbutamol was associated with a reduced early TNFα production
in lungs of mice infected intranasally with NTHi, an effect that was reversed by concurrent
treatment with the β blocker propranolol. The clearance of NTHi from the lungs was impaired in
mice treated with salmeterol or salbutamol, an adverse effect that was prevented by propranolol
and independent of the reduction in TNFα.
Conclusion:  These data suggest that inhalation of salmeterol or salbutamol may negatively
influence an effective clearance of NTHi from the airways.
Background
Chronic obstructive pulmonary disease (COPD) is fre-
quently associated with exacerbations marked by
increased dyspnea, wheezing, cough and increased spu-
tum volume and purulence. Although the causes of such
exacerbations are not always clear, bacterial infections of
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the lower airways may contribute substantially to morbid-
ity, primarily as an evoking event or secondarily as a com-
plication [1,2]. The bacteria most commonly isolated
from patients are non typable Haemophilus influenzae
(NTHi), Streptococcus pneumoniae and Moraxella catarrhalis,
which account for 70 % of all exacerbations of COPD
[1,3].
β2-receptor agonists are frequently used in the treatment
of COPD. These agents induce bronchodilation via activa-
tion of β2-adrenoceptors on smooth muscle cells [4].
Apart from their presence on smooth muscle cells, β2-
receptors are also found on cells involved in the regula-
tion of inflammation like neutrophils, lymphocytes,
monocytes and macrophages [5,6]. Stimulation of β2-
receptors results in a number of anti-inflammatory effects,
including inhibition of neutrophil activation and oxygen
release, reduction of neutrophil-endothelial cell adhesion
and a reduced capacity to release proinflammatory
cytokines such as tumor necrosis factor (TNF)α and inter-
leukin (IL)-1β by macrophages [5,6]. In line with these
findings, we recently demonstrated that salmeterol, a
long-acting β2-agonist, exerted anti-inflammatory effects
in models of lipopolysaccharide (LPS)-induced lung
inflammation in mice and humans, as reflected by a
reduction in lung TNFα levels and an inhibition of neu-
trophil recruitment to the pulmonary compartment [7,8].
We hypothesized that β2 adrenergic agonists such as sal-
meterol or salbutamol would influence the clearance of
NTHi from the respiratory tract. This hypothesis was
based on two lines of evidence. First, the prompt influx of
neutrophils into the lungs is important for the clearance
of NTHi from the airways [9]. Thus, inhibition of neu-
trophil recruitment by salmeterol, such as observed dur-
ing LPS-induced lung inflammation [7,8], may impair
normal host defense. Second, indirect evidence indicates
that TNFα plays a role in the protective immune response
to NTHi, i.e. immunization with formalin killed NTHi
resulted in more pronounced TNFα production which
correlated with enhanced bacterial clearance [10]. Arguing
that endogenous TNFα is of paramount importance for
host defense against other bacterial respiratory pathogens.
[11-14], we considered it conceivable that salmeterol-
induced inhibition of TNFα production, such as found
after pulmonary LPS challenge negatively impacts on the
clearance of NTHi. Therefore, the present study was per-
formed to determine the effects of salmeterol and salbuta-
mol on the immune response to NTHi pneumonia.
Methods
Materials
Salmeterol and salbutamol were kind gifts from Glaxo-
SmithKline (Hertfordshire, United Kingdom). Pro-
pranolol (1 mg/ml) was obtained from Astra Zeneca
(Zoetermeer, The Netherlands).
Bacteriology
H. influenzae strain 12 (kindly donated by S.J. Barenkamp,
St. Louis, MO) is a nontypable clinical isolate that has
been used by our and other laboratories in investigations
on murine pneumonia [15-18]. Classification, storage
and inoculum preparation was performed as described
before [17,18]. The inoculum contained 2 × 108 colony
forming units (CFU) per ml. For each experiment, the
number of CFU was determined by plating serial 10-fold
dilutions on chocolate agar plates.
Cell culture and stimulation
The murine alveolar macrophage cell line MH-S was
obtained from American Type Culture Collection (ATCC
CRL-2019; Rockville, MD). MH-S cells were cultured at
37°C in 5% CO2 in RPMI 1640 medium with 2 mM L-
glutamine adjusted to contain 1.5 g/L sodium bicarbo-
nate, 4.5 g/l glucose, 10 mM Hepes and 1.0 mM sodium
pyruvate and supplemented with 10% FBS, 100 IU/ml
penicillin, 100 µg/ml streptomycin and 0.05 mM 2-mer-
captoethanol. For each experiment cells were seeded in
96-well plates (Greiner, Alphen a/d Rijn, The Nether-
lands) at a density of 0.5 × 105 per well and grown over-
night. The next day cells were washed in medium and
preincubated (5 minutes) with different concentrations of
salmeterol or salbutamol (10-5 – 10-10 M) with or without
propranolol (10-5 M). Salmeterol and salbutamol were
each dissolved to stock concentrations in PBS to which 2
droplets of glacial acetic acid were added. Dilutions of
stock concentrations were made in MH-S medium. Con-
trol solutions were prepared similarly without the addi-
tion of salmeterol or salbutamol. Cells were stimulated
with 5 × 105 heat killed (HK) NTHi (70°C for 30 minutes)
and supernatants were collected after 3, 6, 12 and 24 h
and stored at -20°C until measurement of TNFα.
Mouse studies
Female C57BL/6 mice were purchased from Harlan
Sprague Dawley (Horst, The Netherlands). At the start of
the experiments mice were 8 weeks old. All experiments
were approved by the Animal Care and Use Committee of
the Academic Medical Center (Amsterdam, the Nether-
lands). Pneumonia was induced by intranasal inoculation
of 50 µl (107 CFU) bacterial suspension as described
before [17,18]; control mice received 50 µl sterile PBS.
Mice were pretreated (at -30 minutes) with either control
solution, salmeterol or salbutamol which were nebulized
and inhaled. Salmeterol and salbutamol were each dis-
solved to stock concentrations in PBS to which 2 droplets
of glacial acetic acid were added and dilutions were made
in sterile 0.9% saline. Control solutions were prepared
similarly without the addition of salmeterol or salbuta-Respiratory Research 2006, 7:57 http://respiratory-research.com/content/7/1/57
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mol. Inhalation of 1 ml control solution, salmeterol (2.4
mM) or salbutamol (2.4 mM) was achieved by attaching
a plastic chamber (5 L) containing 8 conscious mice to an
Aeroneb pro nebulizer (Medicare BV, Uitgeest, the Neth-
erlands) as described [7]. Salmeterol and salbutamol
treatments were repeated 6 or 12 hourly respectively until
mice were sacrificed, while mice inhaled control solution
in other groups or at time points they did not not receive
β2-agonists. Propranolol (10 mg/kg) was injected i.p. 30
minutes before salmeterol treatment and repeated every 2
hours to block β-adrenoceptors. In a separate experiment
mice were pretreated i.p. with 250 µg of a neutralizing
anti-mouse TNFα monoclonal antibody (TN3) or mouse
IgG1 (Chemicon, Temecula, CA) 3 hours before inocula-
tion with NTHi; these mice inhaled salmeterol or control
solution 30 minutes before NTHi infection as described
above. TN3 is a well-characterized neutralizing anti-
mouse TNFα monoclonal antibody that effectively neu-
tralized endogenous TNFα in a variety of mouse models
[19-22] including pneumonia [12,14].
Determination of bacterial outgrowth
At 6, 12, 24 or 48 hours after infection mice were sacri-
ficed after which lung and blood CFU were determined as
described before [17,18].
Bronchoalveolar lavage and flow cytometry
Bronchoalveolar lavage (BAL), total and differential cell
count was performed as described [7]. The pellet was
resuspended in FACS buffer (PBS supplemented with 0.5
% BSA, 0.01 % NaN3, and 0.35 mM EDTA) and expres-
sion of CD11b on neutrophils was determined by flow
cytometric analysis as described previously, using rat anti-
mouse CD11b PE and Gr-1 FITC (Ly-6G) antibodies
(Pharmingen, San Diego, CA) [7].
Histologic examination
In separate mice (n = 4 per treatment group at each time
point) whole lungs were harvested for histologic examina-
tion 6 and 48 h after inoculation, fixed in 10 % formalin
and embedded in paraffin. Sections of 4 µm were stained
with hematoxylin and eosin, and analyzed by a patholo-
gist who was blinded for the groups. Lung inflammation
score was determined as described before [17,18].
TNFα measurement and myeloperoxidase (MPO) assay
For TNFα measurement, lung homogenates were diluted
1:1 in lysis buffer (150 mM NaCl, 15 mM Tris, 1 mM
MgCl.H2O, 1 mM CaCl2, 1 mM Triton X-100, 100 µg/ml
Pepstatin A, Leupeptin and Aprotinin, pH 7.4) and incu-
bated at 4°C for 30 minutes. Homogenates were centri-
fuged at 1500 × g for 20 minutes after which the
supernatants were stored at -20°C until TNFα determina-
tion. TNFα was measured using a specific ELISA according
to the manufacturers instructions (R&D Systems, Minne-
apolis, MN). The coefficient of variation was <10%. MPO
activity in lung homogenates was measured as described
previously [23].
Statistical analysis
Values are expressed as mean ± SEM unless indicated oth-
erwise. Differences between groups were analyzed with
the nonparametric Kruskal-Wallis test followed by Mann
Salmeterol and salbutamol inhibit TNFα production by  mouse alveolar macrophages in vitro Figure 1
Salmeterol and salbutamol inhibit TNFα production 
by mouse alveolar macrophages in vitro. MH-S cells 
were incubated with 5 × 105 HKNTHi in the presence or 
absence of salmeterol or salbutamol. A, Effect of salmeterol 
and salbutamol (both 10-7 M) on the kinetics of NTHi-
induced TNFα release. B, Salmeterol and salbutamol inhib-
ited NTHi-induced TNFα release (6 h incubation) in a dose 
dependent fashion, which can be reversed by propranolol 
(10-5 M). Data are mean ± SEM of experiments performed in 
triplo. Please note that error bars fall within the symbols at 
multiple time points and concentrations. Markers of signifi-
cance (described in the Results section) were omitted for 
reasons of clarity (figure 1B).
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Whitney U as posttest. P < 0.05 (two-sided) was consid-
ered statistically significant.
Results
Salmeterol and salbutamol inhibit TNFα production by 
mouse alveolar macrophages stimulated with heat killed 
NTHi
To determine whether β2 agonists inhibit TNFα release by
alveolar macrophages stimulated with NTHi, MH-S cells
were incubated with HKNTHi and supernatants were har-
vested after various time periods (figure 1A). Addition of
5 × 105 HKNTHi to mouse MH-S alveolar macrophages
resulted in a rapid and sustained release of TNFα in cul-
ture medium reaching 13.73 ± 0.67 and 22.88 ± 2.67 ng/
ml respectively after 6 and 24 h (figure 1A: p < 0.05 for
NTHi stimulated vs unstimulated cells at all timepoints).
NTHi-induced TNFα production was strongly inhibited
by the β2-adrenoceptor agonists salmeterol and salbuta-
mol (both 10-7 M) at almost all incubation durations
tested (figure 1A: p < 0.05 for salmeterol and salbutamol
vs medium, except for salmeterol at t = 3 h). Inhibition of
TNFα release by salmeterol or salbutamol occurred in a
dose-dependent fashion (figure 1B). The inhibitory effect
of both β2 agonists could be reversed by co-incubation
with the β receptor blocker propranolol (10-5 M) except
for when very high doses of β2 agonists were used (figure
1B). Of note, stimulation of MH-S cells with NTHi in the
presence of propranolol alone resulted in enhanced TNFα
release (figure 1B).
Salmeterol and salbutamol inhalation inhibit TNFα 
production in mouse lungs infected with NTHi
Intranasal inoculation of mice with 107 CFU NTHi signif-
icantly increased pulmonary TNFα concentrations, peak-
ing after 6 hours (figure 2A: p < 0.05 versus non-infected
mice at all time points). Inhalation of nebulized salme-
terol reduced lung TNFα concentrations in NTHi infected
mice, which reached significance at 6 hours post-chal-
lenge. The salmeterol induced reduction TNFα in lung
homogenates and BALF at 6 hours post-infection was
reversed by propranolol treatment (figure 2B and 2C: p <
0.05 versus salmeterol). Inhalation of salbutamol at equi-
molar concentrations as salmeterol also reduced TNFα in
lung homogenates and BALF 6 h after infection with NTHi
although in lung homogenates the difference with vehicle
did not reach statistical significance (figure 2B and 2C: p
< 0.05 versus vehicle in BALF).
Salmeterol does not influence neutrophil influx or CD11b 
expression
Intranasal inoculation of mice with 107  CFU NTHi
resulted in a rapid pulmonary neutrophil influx (as meas-
ured by MPO activity) which was already strongly
enhanced 6 hours post-infection, remaining high
throughout the 48-hour observation period (figure 3A: p
< 0.05 versus non-infected mice at all time points). Inha-
lation of nebulized salmeterol did not alter the neutrophil
response to NTHi challenge. Additionally, neutrophil
Inhalation of salmeterol or salbutamol attenuate TNFα pro- duction in NTHi infected lungs in vivo Figure 2
Inhalation of salmeterol or salbutamol attenuate 
TNFα production in NTHi infected lungs in vivo. Mice 
inhaled salmeterol or salbutamol before intranasal inocula-
tion with 107 CFU NTHi. Some mice were injected with pro-
pranolol i.p. (10 mg/kg every 2 h). A, Salmeterol reduced 
TNFα production in NTHi infected lung homogenates 6 h 
post-challenge. The effect of salmeterol on TNFα production 
6 h post-infection was mimicked by salbutamol and antago-
nized by propranolol in lung homogenates (B) and BALF (C). 
Values are mean ± SEM of 8 mice per group. * P < 0.05 ver-
sus vehicle and versus salmeterol + propranolol.
0 12 24 36 48
0
2500
5000
7500
Vehicle
Salmeterol
A
*
Time (h)
T
N
F
D
 
(
p
g
/
m
l
)
0
1000
2000
3000
4000
Vehicle
Salmeterol
Salmeterol+
propranolol
Salbutamol
*
B
T
N
F
D
 
(
p
g
/
m
l
)
0
1000
2000
3000
Vehicle
Salmeterol
Salmeterol+
propranolol
Salbutamol
* *
C
T
N
F
D
 
(
p
g
/
m
l
)Respiratory Research 2006, 7:57 http://respiratory-research.com/content/7/1/57
Page 5 of 10
(page number not for citation purposes)
influx in BALF was strongly increased 6 hours after NTHi
administration (p < 0.05 versus non-infected mice (data
not shown)) which was not modulated by salmeterol or
salbutamol. The expression of CD11b on neutrophils in
BALF was not affected by salmeterol and was modestly but
significantly decreased by salbutamol treatment (figure
3C: p < 0.05 versus vehicle).
Salmeterol treated mice display unaltered pulmonary 
inflammation after NTHi challenge
Histologic examination of lungs at 6 hours post-infection
revealed mild interstitial inflammation, edema and
endothelialitis which were not different between vehicle
and salmeterol treated mice (figure 4A and 4B). At 48
hours post-infection, lungs of mice displayed diffuse
inflammation with moderate interstitial infiltrates, alveo-
litits, endothelialitis and pleuritis (figure 4C). The infil-
trates consisted predominantly of granulocytes.
Salmeterol treated mice showed unaltered pulmonary
inflammation as assessed by the overall inflammation
score which was 13.0 ± 2.1 and 10.5 ± 1.5 in vehicle and
salmeterol treated mice respectively (Figure 4C and 4D).
No difference in inflammatory cell type composition was
observed after treatment with salmeterol.
Salmeterol and salbutamol impair the clearance of NTHi 
from lungs
To study the consequence of salmeterol inhalation for
pulmonary anti-microbial defense the bacterial load was
determined at various time points after NTHi infection. As
reported earlier, intranasal inoculation of mice with 107
CFU NTHi did not result in lethality, with bacterial loads
showing a gradual decline over several days [17,18]. Inha-
lation of salmeterol reduced the clearance of NTHi at 24
and 48 hours post-infection (figure 5A: p < 0.05 versus
vehicle). At 6 hours no difference in bacterial clearance
between control and salmeterol treated mice was
observed, while at 12 hours post-NTHi bacterial load in
salmeterol mice was slightly decreased (figure 5A).
Although at this 12-hour time point difference was statis-
tically significant, the biological significance is likely to be
low, especially since we repeatedly found higher bacterial
loads in mice treated with salmeterol at 24 hours post
infection. Indeed, in a separate experiment, inhalation of
salmeterol again was associated with more NTHi CFU in
lung homogenates 24 h postinfection (figure 5B: p < 0.05
versus vehicle), an effect that was reversed by propranolol
(figure 5B: p < 0.05 versus salmeterol). Moreover, also
salbutamol inhalation resulted in an enhanced pulmo-
nary bacterial load at this time point. In this model of
pneumonia, blood cultures remained sterile at all time
points.
TNFα is not essential for the clearance of NTHi from 
mouse lungs
One obvious explanation for the decreased bacterial clear-
ance observed in salmeterol treated mice was the inhib-
ited production of TNFα. Therefore, mice received an anti-
TNFα or matched control antibody prior to inhalation of
salmeterol or vehicle (figure 6). In this experiment, salm-
eterol again increased the bacterial load at 24 hours post-
infection (p < 0.05 versus vehicle). Remarkably, anti-
TNFα did not influence the number of NTHi CFU in lungs
of mice treated with either salmeterol or vehicle, indicat-
ing that TNFα was not essential for the bacterial clearance
in NTHi infected lungs.
Discussion
H. influenzae is a Gram-negative pathogen that frequently
colonizes human respiratory mucosa. Nontypable strains
are responsible for the majority of clinical disease caused
by H. influenzae in the airways, and in particular patients
with COPD, bronchiectasis and cystic fibrosis are suscep-
tible to infection with NTHi [24]. We here tested the
hypothesis that inhalation of β2 agonists, a treatment
often given to patients with COPD and other chronic pul-
monary disorders that predispose subjects to NTHi infec-
tion, would negatively influence host defense against this
bacterium. Our results provide evidence that inhalation of
either salmeterol or salbutamol indeed impairs the clear-
ance of NTHi from the mouse respiratory tract in vivo.
Our hypothesis was, in part, based on our recent studies
that investigated the effect of salmeterol on LPS-induced
lung inflammation [7,8]. In these studies it was estab-
lished that inhalation of salmeterol attenuated neutrophil
influx into lungs after intrapulmonary delivery of LPS,
concurrently reducing pulmonary TNFα concentrations.
Here, we demonstrated that both salmeterol and salbuta-
mol dose-dependently inhibit TNFα release by mouse
alveolar macrophages stimulated with NTHi in vitro and
that inhalation of either β2 agonist was associated with
lower TNFα concentrations in lung tissue and BALF dur-
ing NTHi pneumonia in vivo. The β2 agonist induced
inhibition of TNFα release could be reversed by pro-
pranolol, indicating that the effect of these agents is medi-
ated by β adrenergic receptors. Earlier studies reported on
the systemic effects of β adrenergic agonists on TNFα
release into the circulation after systemic (intravenous or
intraperitoneal) administration of LPS [25-27].
We considered it conceivable that the reduced TNFα levels
in β2 agonist treated mice was at least in part responsible
for the impaired clearance of NTHi from the lungs. This
assumption was based on various earlier findings. First,
inhibition of TNFα in murine models of pneumonia
caused by several respiratory pathogens, including Kleb-
siella pneumoniae and Streptococcus pneumoniae, resulted inRespiratory Research 2006, 7:57 http://respiratory-research.com/content/7/1/57
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a strongly enhanced bacterial outgrowth. [11-14]. Second,
immunization with formalin killed NTHi accelerated bac-
terial clearance which was accompanied by increased
TNFα production [10]. However, the present data clearly
establish that TNFα does not contribute to an effective
clearance of NTHi from the airways. The same anti-TNFα
antibody that strongly impaired host defense during
pneumonia caused by S. pneumoniae [12] or K. pneumoniae
[14] did not influence the bacterial load during NTHi
pneumonia. Moreover, anti-TNFα treatment did also not
alter the effect of inhaled salmeterol on NTHi clearance.
Interestingly, it was previously reported that mice defi-
cient for the type I TNFα receptor displayed a modestly
enhanced early clearance of Pseudomonas aeruginosa from
the lungs during acute pneumonia [28]. Altogether these
investigations suggest that early TNFα production in the
lung is important for limiting the outgrowth of respiratory
pathogens in the pulmonary compartment (i.e. S. pneumo-
niae  and  K. pneumoniae multiply in the mouse lung),
whereas locally induced TNFα is of little importance for
the immune response against bacteria that are cleared
from the lungs (i.e. P. aeruginosa and NTHi) ([28] and the
present study). A similar paradoxical role in murine pneu-
monia has been found for another prototypic proinflam-
matory cytokine IL-1, which facilitates host defense
against S. pneumoniae [13,29], while having a modest neg-
ative impact on the clearance of P. aeruginosa [30]. It
should be noted that in the current study we did not
directly determine the capacity of anti-TNFα to neutralize
TNFα activity in the lungs of mice infected with NTHi.
Therefore, definitive proof that TNFα does not play a role
in host defense against NTHi in this model is not pro-
vided. To obtain more insight into the role of TNF in host
defense against NTHi pneumonia studies using TNFα or
TNF receptor deficient mice are warranted. In addition,
the potential protective effect of exogenous TNFα in mice
treated with salmeterol could be evaluated using adenovi-
ral TNFα gene transfer.
Neutrophils play an important role in the clearance of
NTHi from the respiratory tract [9]. Neither salmeterol
nor salbutamol influenced the recruitment of neutrophils
to the lungs after infection with NTHi, as reflected by an
unaltered number of neutrophils in BALF and in lung tis-
sue slides, as well as by a similar rise in lung MPO concen-
trations in mice treated with salmeterol. This finding
contrasts with the strong effect of salmeterol on influx of
neutrophils into the pulmonary compartment after local
delivery of LPS [7,8]. Notably, neutrophil emigration
from the pulmonary circulation during inflammation
caused by Gram-negative stimuli relies largely on expres-
sion of the β2 integrin CD11b/CD18 at the surface of neu-
trophils [31]. We recently demonstrated that salmeterol
reduces CD11b expression on neutrophils recruited to the
lung after intranasal administration of LPS and that block-
ing CD11b on neutrophils reproduces the inhibition of
neutrophil influx by salmeterol treatment [7]. This led us
to conclude that the effect of salmeterol on neutrophil
influx during LPS-induced lung inflammation was at least
in part due to a salmeterol-induced reduction in neu-
trophil CD11b expression [7]. In the present study, salm-
eterol did not influence neutrophil CD11b expression
during NTHi infection, whereas salbutamol only had a
Inhalation of salmeterol or salbutamol does not modulate  neutrophil influx Figure 3
Inhalation of salmeterol or salbutamol does not modulate 
neutrophil influx. Mice inhaled salmeterol or salbutamol 
before intranasal inoculation with 107 CFU NTHi. Some mice 
were injected with propranolol i.p. (10 mg/kg every 2 h). A, 
Salmeterol did not alter neutrophil influx in NTHi infected 
lungs as determined by whole lung MPO activity. Addition-
ally, no effect of salmeterol or salbutamol could be observed 
on neutrophil influx in BALF at 6 h after NTHi infection (B). 
C, Salbutamol but not salmeterol reduced CD11b expression 
on BALF neutrophils. Values are mean ± SEM of 8 mice per 
group. * P < 0.05 versus vehicle.
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modest effect. We do not have a firm explanation for these
apparently different effects of salmeterol and salbutamol
on neutrophil CD11b, although clearly the effect of salb-
utamol is weak and of doubtful biological relevance. Con-
ceivably, this lack of a strong effect on neutrophil CD11b
at least in part explains the present finding that inhalation
of β2 agonists did not affect neutrophil trafficking to the
lung. Further studies are warranted to assess whether the
impact of β2 agonists on neutrophil functions only
applies to sterile stimuli eliciting a brisk but transient
inflammatory response in the lung (e.g. such as induced
by LPS).
Salmeterol achieves instantaneous topical concentrations
at least as high as 1 µM in human lung [32]. In vitro, sal-
meterol and salbutamol inhibited TNFα production by
alveolar macrophages at concentrations as low as 0.1–10
nM (figure 1B), a concentration range that appears to be
clinically relevant. In guinea pigs, inhaled salmeterol
(0.12–12 mM) and salbutamol (0.2 and 2 mM) strongly
inhibited histamine-induced bronchoconstriction which
was argued to be of predictive value in terms of relative
potencies and durations of action of inhaled β2 agonists
in man [33]. In the present study the doses of salbutamol
and salmeterol (both 2.4 mM) were well within the effec-
tive range as tested in guinea pigs, and proved to be effec-
Inhalation of salmeterol does not influence inflammation in NTHi infected lungs Figure 4
Inhalation of salmeterol does not influence inflammation in NTHi infected lungs. Mice inhaled vehicle (A, C) or sal-
meterol (B, D) before intranasal inoculation with 107 CFU NTHi. Mice (n = 4 per group) were sacrificed 6 (A, B) and 48 hours 
(C, D) post-infection and whole lungs were examined for inflammation. At 6 h post-infection, all mice displayed mild inflamma-
tion while at 48 h lung inflammation was more pronounced and diffuse. The inflammation scored did not reveal a difference 
between vehicle and salmeterol treated animals at both timepoints. H&E staining, magnification 10×.Respiratory Research 2006, 7:57 http://respiratory-research.com/content/7/1/57
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tive and propranolol sensitive (β receptor dependent)
with respect to inhibition of both TNFα production and
bacterial clearance after NTHi challenge. Together, these
data suggest that salmeterol and salbutamol as nebulized
in our model is present in lungs in sufficiently high topi-
cal and probably clinically relevant concentrations to
cause β-adrenoceptor dependent inhibition of TNFα pro-
duction and bacterial clearance in NTHi infected lungs.
It should be noted that our studies with salbutamol were
focused on the most relevant time point of the time course
studies using salmeterol. In addition, we did not deter-
mine the effect of propranolol in salbutamol treated mice.
The salbutamol studies were done to exclude a salmeterol
specific effect and to show that the effects observed were
specific for the class of β2 agonists. Considering that both
salmeterol and salbutamol inhibited the clearance of
NTHi, our investigation provides proof for an effect that
indeed is mediated by stimulation of β2 receptors.
Salmeterol and salbutamol consistently delayed the clear-
ance of NTHi from the lungs, a finding that was repro-
duced in several experiments (figure 5A, 5B and 6).
Considering that the β2 agonist induced inhibition of
early TNFα release can not explain the adverse effect of
salmeterol and salbutamol on the bacterial clearance, and
considering that these agents did not influence neutrophil
recruitment, other mechanisms must be involved. In this
respect it should be noted that β2 agonists can inhibit sev-
eral inflammatory cell functions considered important for
defense against bacteria. For instance neutrophil respira-
tory burst activity [34] and exocytosis [35] were shown to
be attenuated by β2 agonist treatment. Additionally, bac-
terial killing and superoxide anion release by alveolar
macrophages was strongly suppressed by both salbutamol
and formoterol [36]. In contrast, no effect of β2 agonists
on phagocytosis by neutrophils and alveolar macro-
phages was observed [37,38]. Other studies have docu-
mented possible protective effects of β2 agonists on
respiratory epithelium. In particular, preincubation of
human nasal turbinates with salmeterol attenuated H.
influenzae reduced epithelial damage without influencing
the total number of bacteria adhering to the organ culture
[39]. Similar observations have been made in nasal tur-
binate cultures infected with P. aeruginosa [40].
Conclusion
Our study suggests that, at least in mice, inhalation of β2
agonists impairs the clearance of NTHi from the airways.
Obviously, these data do not imply that the use of β2 ago-
nists should be discouraged in patients with obstructive
pulmonary diseases; rather they exemplify the complex
anti-inflammatory actions of β2 agonists in the pulmo-
nary compartment and that a potential role in the sup-
pression of pulmonary antibacterial defenses must not be
overlooked.
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